2.50
Hdl Handle:
http://hdl.handle.net/10033/620605
Title:
Therapy of solid tumors using probiotic Symbioflor-2: restraints and potential.
Authors:
Kocijancic, Dino; Felgner, Sebastian; Frahm, Michael; Komoll, Ronja-Melinda; Iljazovic, Aida; Pawar, Vinay; Rohde, Manfred ( 0000-0003-0522-3580 ) ; Heise, Ulrike; Zimmermann, Kurt; Gunzer, Florian; Hammer, Juliane; Crull, Katja; Leschner, Sara; Weiss, Siegfried
Abstract:
To date, virulent bacteria remain the basis of most bacteria mediated cancer therapies. For clinical application attenuation is required. However, this might result in a drastically lowered therapeutic capacity. Herein we argue that the E. coli probiotic Symbioflor-2, with a history of safe application may constitute a viable tumor therapeutic candidate. We demonstrate that Symbioflor-2 displays a highly specific tumor targeting ability as determined in murine CT26 and RenCa tumor models. The excellent specificity was ascribed to reduced levels of adverse colonization. A high safety standard was demonstrated in WT and Rag1-/- mice. Thus, Symbioflor-2 may represent an ideal tumor targeting delivery system for therapeutic molecules. Moreover, Symbioflor-2 was capable of inducing CT26 tumor clearance as result of an adjuvant effect on tumor specific CD8+ T cells analogous to the Salmonella variant SL7207. However, lower therapeutic efficacy against RenCa tumors suggested a generally reduced therapeutic potency for probiotics. Interestingly, concurrent depletion of Gr-1+ or Ly6G+ cells installed therapeutic efficacy equal to SL7207, thus highlighting the role of innate effector cells in restraining the anti-tumor effects of Symbioflor-2. Collectively, our findings argue for a strategy of safe strain application and a more sustainable use of bacteria as a delivery system for therapeutic molecules.
Affiliation:
Helmholtz Centre for infection research, Inhoffenstr. 7, 38124 Braunschweig, Germany.
Citation:
Therapy of solid tumors using probiotic Symbioflor-2: restraints and potential. 2016, 7 (16):22605-22 Oncotarget
Journal:
Oncotarget
Issue Date:
19-Apr-2016
URI:
http://hdl.handle.net/10033/620605
DOI:
10.18632/oncotarget.8027
PubMed ID:
26981777
Type:
Article
Language:
en
ISSN:
1949-2553
Appears in Collections:
publications of the research group molecular Immunology (MOLI)

Full metadata record

DC FieldValue Language
dc.contributor.authorKocijancic, Dinoen
dc.contributor.authorFelgner, Sebastianen
dc.contributor.authorFrahm, Michaelen
dc.contributor.authorKomoll, Ronja-Melindaen
dc.contributor.authorIljazovic, Aidaen
dc.contributor.authorPawar, Vinayen
dc.contributor.authorRohde, Manfreden
dc.contributor.authorHeise, Ulrikeen
dc.contributor.authorZimmermann, Kurten
dc.contributor.authorGunzer, Florianen
dc.contributor.authorHammer, Julianeen
dc.contributor.authorCrull, Katjaen
dc.contributor.authorLeschner, Saraen
dc.contributor.authorWeiss, Siegfrieden
dc.date.accessioned2016-11-29T09:04:51Z-
dc.date.available2016-11-29T09:04:51Z-
dc.date.issued2016-04-19-
dc.identifier.citationTherapy of solid tumors using probiotic Symbioflor-2: restraints and potential. 2016, 7 (16):22605-22 Oncotargeten
dc.identifier.issn1949-2553-
dc.identifier.pmid26981777-
dc.identifier.doi10.18632/oncotarget.8027-
dc.identifier.urihttp://hdl.handle.net/10033/620605-
dc.description.abstractTo date, virulent bacteria remain the basis of most bacteria mediated cancer therapies. For clinical application attenuation is required. However, this might result in a drastically lowered therapeutic capacity. Herein we argue that the E. coli probiotic Symbioflor-2, with a history of safe application may constitute a viable tumor therapeutic candidate. We demonstrate that Symbioflor-2 displays a highly specific tumor targeting ability as determined in murine CT26 and RenCa tumor models. The excellent specificity was ascribed to reduced levels of adverse colonization. A high safety standard was demonstrated in WT and Rag1-/- mice. Thus, Symbioflor-2 may represent an ideal tumor targeting delivery system for therapeutic molecules. Moreover, Symbioflor-2 was capable of inducing CT26 tumor clearance as result of an adjuvant effect on tumor specific CD8+ T cells analogous to the Salmonella variant SL7207. However, lower therapeutic efficacy against RenCa tumors suggested a generally reduced therapeutic potency for probiotics. Interestingly, concurrent depletion of Gr-1+ or Ly6G+ cells installed therapeutic efficacy equal to SL7207, thus highlighting the role of innate effector cells in restraining the anti-tumor effects of Symbioflor-2. Collectively, our findings argue for a strategy of safe strain application and a more sustainable use of bacteria as a delivery system for therapeutic molecules.en
dc.languageENG-
dc.language.isoenen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleTherapy of solid tumors using probiotic Symbioflor-2: restraints and potential.en
dc.typeArticleen
dc.contributor.departmentHelmholtz Centre for infection research, Inhoffenstr. 7, 38124 Braunschweig, Germany.en
dc.identifier.journalOncotargeten

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.